You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

  • Authors: Suresh S. Ramalingam, MD; Giorgio V. Scagliotti, MD, PhD; Panagiotis Fidias, MD; Jared Weiss, MD; H. Jack West, MD; Hossein Borghaei, DO
  • CME Released: 6/22/2015
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/22/2016
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, and other members of oncology care teams.

The goal of this activity is to review the latest clinical data as presented at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO®) for the treatment of patients with advanced non-small cell lung cancer (NSCLC).

Upon completion of this activity, participants will be able to:

  1. Evaluate emerging agents that target regulation of the immune system and their potential role in the care of patients with advanced NSCLC
  2. Detail the role of tumor characteristics including the use of histology, genotype, and protein expression in selecting treatment for patients with advanced NSCLC
  3. Identify advances in the treatment of advanced NSCLC that has progressed on first-line therapy or become resistant to molecularly targeted therapy
  4. Assess clinical trial data evaluating investigational agents for the treatment of advanced NSCLC presented at the ASCO® 2015 Annual Meeting
  5. Discuss how new data presented at the ASCO® 2015 Annual Meeting on treatment strategies for advanced NSCLC might affect current standards in community practice


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Authors

  • Suresh S. Ramalingam, MD

    Professor of Hematology/Oncology; Director, Lung Cancer Program, Winship Cancer Institute, Emory University, Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Ramalingam and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Ramalingam's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosure: Suresh S. Ramalingam, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Lilly

    Dr Ramalingam does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ramalingam does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Giorgio V. Scagliotti, MD, PhD

    Professor of Medical Oncology; Chief, Department of Oncology, University of Turin at San Luigi Hospital, Turin, Italy

    Disclosures

    Disclosure: Giorgio V. Scagliotti, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Lilly
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Clovis Oncology; Lilly; Pfizer Inc; Roche

    Dr Scagliotti does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Scagliotti does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Panagiotis Fidias, MD

    Associate Professor of Medicine, Harvard Medical School; Member, Thoracic Oncology Service, Massachusetts General Hospital, Boston, Massachusetts

    Disclosures

    Disclosure: Panagiotis Fidias, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.

    Dr Fidias does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Fidias does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Jared Weiss, MD

    Assistant Professor of Medicine, Division of Hematology and Oncology, University of North Carolina School of Medicine; Attending Physician, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Disclosures

    Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biodesix, Inc.; Clovis Oncology; OncoPlexDx
    Received grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; GlaxoSmithKline; Pfizer Inc

    Dr Weiss does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Weiss does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • H. Jack West, MD

    Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington

    Disclosures

    Disclosure: H. Jack West, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Guardant Health, Inc.; Roche

    Dr West does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr West does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Hossein Borghaei, DO

    Associate Professor, Medical Oncology; Chief, Thoracic Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Hossein Borghaei, DO, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Lilly
    Received grants for clinical research from: Millennium Pharmaceuticals, Inc.

    Dr Borghaei does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Borghaei does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Joanne M. Faysal, MS

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joanne M. Faysal, MS, has disclosed no relevant financial relationships.

CME Reviewer

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

New Horizons in Advanced Non-small Cell Lung Cancer: Highlights from Chicago

Authors: Suresh S. Ramalingam, MD; Giorgio V. Scagliotti, MD, PhD; Panagiotis Fidias, MD; Jared Weiss, MD; H. Jack West, MD; Hossein Borghaei, DOFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 6/22/2015

Valid for credit through: 6/22/2016

processing....

Editor’s Note: On October 9, 2015, after filming of this activity, the U.S. Food and Drug Administration (FDA) expanded its approval of nivolumab for use in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. In addition, on November 13, 2015, the FDA granted accelerated approval to osimertinib (AZD9291) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. On November 24, 2015, the U.S. FDA approved necitumumab for use in combination with gemcitabine and cisplatin in patients with metastatic squamous NSCLC who have not been previously treated. Finally, on December 11, 2015, the FDA granted an accelerated approval for alectinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Emerging Therapies in EGFR-Resistant NSCLC
Dr Ramalingam reviews the latest clinical data on emerging therapies for patients with T790M EGFR mutations.
Suresh S. Ramalingam, MD
Section 2. Current and Future Directions in the Treatment of ALK-Resistant NSCLC
Dr Scagliotti discusses the efficacy and safety of second-generation ALK inhibitors.
Giorgio V. Scagliotti, MD, PhD
Section 3. Targeting Novel Biomarkers in Advanced NSCLC
Dr Fidias reviews recent data on therapies that target the MET pathway and BRAF V600K mutations.
Panagiotis Fidias, MD
Section 4. Clinical Advances in NSCLC: Emerging Chemotherapy Options
Dr Weiss provides analysis of the latest chemotherapeutic agents in clinical trials.
Jared Weiss, MD
Section 5. Advances and Perspectives in Squamous Cell NSCLC
Dr West examines recent data on emerging therapies for the treatment of squamous cell NSCLC.
H. Jack West, MD
Section 6. Immunotherapy in NSCLC: PD-1 and PD-L1 Inhibitors
Dr Borghaei offers in-depth insight into PD-1 and PD-L1 inhibitors for advanced NSCLC.
Hossein Borghaei, DO

Educational Impact Challenge

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print